Trials / Terminated
TerminatedNCT05405790
Antibiotic Prophylaxis for TEVAR
Antibiotic Prophylaxis for Thoracic EndoVascular Aortic Repair
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 457 (actual)
- Sponsor
- First Affiliated Hospital of Zhejiang University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The infection rate of thoracic endovascular aortic repair (TEVAR) is unknown due to a lack of epidemiological data. The rate currently available comes from researches conducted decades ago, when open surgery was the standard of care. Because of the potentially fatal consequences of a stent graft infection in the thoracic aorta, the investigators tend to prescribe antibiotic prophylaxis for at least three days. In this study, the investigators are going to collect data on patients receiving TEVAR in the past five years and provide the following information: a. the infection rate (MAGIC classification), b. the rate of fever, c. the results of the lab tests, such as the WBC count and C-reaction protein. d. risk factors associated with infection and fever.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | thoracic endovascular aortic repair | In The TEVAR procedure, we implant a stent graft into the diseased area of the thoracic artery, providing a route for the blood to flow within the stent graft and excluding the diseased aorta. |
Timeline
- Start date
- 2022-01-01
- Primary completion
- 2023-01-01
- Completion
- 2025-09-01
- First posted
- 2022-06-06
- Last updated
- 2025-09-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05405790. Inclusion in this directory is not an endorsement.